Autopsy report · NCT00783471
Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
Cause of deathSlow enrollment
“The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment arms.”
Life of this trial
- Ran for about 1 year 7 months before it stopped.
- 51 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Hellenic Cooperative Oncology Group
- Sponsor type
- University, hospital or other
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- Erlotinib, Docetaxel; Docetaxel, Erlotinib
- Participants
- 51
- Sites
- 13
- Countries
- Greece
Trials that died the same way
- A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
“Changes in treatment paradigm resulted in a lower than expected rate of accrual.” - Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
“the study had a low accrual rate” - CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
“low accrual made the study no longer feasible/decision not related to safety and efficacy” - A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
“Study closed due to slow accrual and lack of efficacy.” - Pre-operative Zoledronate in Triple Negative Breast Cancer
“The study stopped prematurely due to the low accrual rate”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.